MedTrace Logo

Determining Drug Levels of Beta-lactam Antibiotics in Severe Burned Patients

NCT03335137 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2017-11-07

No results posted yet for this study

Summary

At antibiotic stewardship of the University Hospital of Schleswig-Holsten it was noticed that there are much less studies measuring drug levels in severe burned patients than are required. Especially, severe burned patient developing a capillary leak might show lower drug levels than patients without a capillary leak. To compare drug levels of beta-lactam antibiotics, it is the aim of this study to measure pharmacokinetics of Piperacillin/Tazobactam in ICU patients with and without severe burns.

Conditions

  • Antibiotics
  • Severe Burn
  • Intensive Care

Interventions

DIAGNOSTIC_TEST

Drug Level Monitoring

Free (unbound) drug concentration 1 hour, 4 hours and 7.5 hours after primary load of piperacillin/tazobactam on day 1 and day 3 after admission

Sponsors & Collaborators

  • Medical Clinic III

    collaborator UNKNOWN

  • Dezernat Apotheke

    collaborator UNKNOWN

  • University Hospital Schleswig-Holstein

    lead OTHER

Principal Investigators

  • Peter Mailänder, PhD · Plastic and Reconstructive Surgery, Hand Surgery, Burn Unit

  • Walter Raasch, PhD · Institute for experimental and clinical pharmacology and toxicology

  • Tobias Kisch, MD · Plastic and Reconstructive Surgery, Hand Surgery, Burn Unit

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-01
Primary Completion
2016-05-31
Completion
2016-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03335137 on ClinicalTrials.gov